XNCR Q4 2023 Earnings — Xencor, Inc. Revenue & Financial Results | Market Cap Arena

XNCRXencor, Inc.

$890M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M+135.8% YoY

Gross Profit

$48M93.7% margin

Operating Income

-$29M-56.4% margin

Net Income

-$26M-51.3% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

-13.9%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$17M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$965M

Total Liabilities

$303M

Stockholders' Equity

$662M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$22M	+135.8%
Gross Profit	$48M	-$30M	+260.0%
Operating Income	-$29M	-$43M	+32.5%
Net Income	-$26M	-$12M	-117.1%

Revenue Segments

Milestone

$28M62%

Research collaboration

$9M21%

Royalty

$8M18%